Cyclo Therapeutics, Inc. provided updates for the Company's Trappsol® Cyclo™ clinical program and provided a summary of key achievements in 2022, focused on clinical portfolio of two neurodegenerative diseases with major unmet medical needs Trappsol® Cyclo™ is the Company's proprietary formulation of hydroxypropyl beta cyclodextrin, used intravenously (IV) and currently in development for the treatment of NPC, a rare genetic disorder causing cholesterol accumulation in lysosomes of cells, organ dysfunction and premature death, and early Alzheimer's Disease (AD), where disrupted lipid pathways play a key role in the etiology and disease progression. Continued progress in patient enrollment with 35% in the ongoing TransportNPC™ study completed to-date and dosing ongoing across multiple regions; · Announced the publication of Phase 1 data for Trappsol® Cyclo™ for the treatment of NPC in the official journal of the Society for Inherited Metabolic Disorders, Molecular Genetics and Metabolism; · Attended the 2022 NPUK Annual Family Conference & Interactive Workshop on Niemann-Pick Disease with Caroline Hastings, M.D., Key Opinion Leader in NPC and Global Principal Investigator for the ongoing TransportNPC™ study, to connect with the global NPC community and discuss Trappsol® Cyclo™ and its clinical development program for the treatment of NPC; · Announced the formation of Global Steering Committee comprised of leading experts to advise on the global Phase 3 clinical development program for Trappsol® Cyclo™ in NPC; · Lise Kjems, MD, PhD and Chief Medical Officer, presented at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association, a physician, researcher and patient focused event to discuss NPC and the latest research results for diagnosis and treatment; · Attended the NNPDF-INPDA Conferences 2022 with Caroline Hastings, M.D., Key Opinion Leader in NPC and Global Principal Investigator for the ongoing TransportNPC™ study, to discuss Trappsol® Cyclo™ and its clinical development program for the treatment of NPC; · Provided an overview of the Trappsol® Cyclo™ program for the treatment of NPC at the World Orphan Drug Congress USA 2022 with Lise Kjems CMO as invited speaker · Presence at World Symposium USA 2022 with Lise Kjems presenting TransportNPC study design and key considerations · Presented an update on the results from Phase 1 and Phase ½ studies and launch of the international Phase 3 pivotal TransportNPC™ trial at the 2022 NPC Patient and Family Conference hosted by the Australian NPC Disease Foundation; and · Dr. Kjems invited as speaker at BioFlorida 2022 Rare Disease Session.